Get the Stockscreener App
18.07
1.69%
-0.31
After Hours:
18.07
Immunome Inc stock is traded at $18.07, with a volume of 905.11K.
It is down -1.69% in the last 24 hours and down -13.46% over the past month.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
See More
Previous Close:
$18.38
Open:
$18.63
24h Volume:
905.11K
Relative Volume:
0.75
Market Cap:
$2.05B
Revenue:
$4.02M
Net Income/Loss:
$-224.59M
P/E Ratio:
-7.594
EPS:
-2.3795
Net Cash Flow:
$-205.52M
1W Performance:
-2.90%
1M Performance:
-13.46%
6M Performance:
-20.19%
1Y Performance:
+96.41%
1-Day Range:
$17.95
$18.73
1-Week Range:
$17.95
$19.19
52-Week Range:
$7.96
$27.65
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
18.07 | 2.08B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
How Immunome’s First-in-Human IM-1617 ADC Trial At Immunome (IMNM) Has Changed Its Investment Story - simplywall.st
IMNM (NASDAQ: IMNM) director plans to sell 60,000 shares via option - Stock Titan
Immunome (IMNM) director receives 9,897 stock options at $18.16 strike price - Stock Titan
[Form 4] Immunome Inc. Insider Trading Activity - Stock Titan
Immunome (IMNM) director granted stock options on 9,897 common shares - Stock Titan
Immunome (IMNM) director-linked entity awarded 9,897 stock options at $18.16 strike - Stock Titan
Immunome (IMNM) director Carol Schafer receives grant of 9,897 stock options - Stock Titan
Immunome (IMNM) 2026 meeting: directors elected, pay and auditor votes pass - Stock Titan
IMNM Reiterated by Wedbush -- Price Target Maintained at $31 - GuruFocus
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Immunome (IMNM) Begins First Phase 1 Trial for IM-1617 - GuruFocus
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - BioSpace
Immunome doses first patient in IM-1617 cancer therapy trial - Investing.com
Immunome director Bienaime sells $203k, buys $204k in same-day trades By Investing.com - Investing.com Australia
Immunome director Bienaime sells $203k, buys $204k in same-day trades - Investing.com Australia
IMNM SEC FilingsImmunome Inc 10-K, 10-Q, 8-K Forms - Stock Titan
IMNM: Varegacestat nears launch with strong data; ADC pipeline advances with key readouts ahead - TradingView
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis (NASDAQ:IMNM) - Seeking Alpha
Can Varegacestat’s Broad Efficacy Profile Redefine Immunome’s (IMNM) Rare Oncology Investment Narrative? - simplywall.st
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Immunome earnings up next: Cash burn eyed after NDA filing By Investing.com - Investing.com UK
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA FilingHas The Bull Case Changed? - Yahoo Finance
Immunome earnings up next: Cash burn eyed after NDA filing - Investing.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - standard-journal.com
A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage - Sahm
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33 - Moomoo
H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Barclays Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome (IMNM) Reveals Promising Results in Phase 3 Trial of Va - GuruFocus
Immunome (IMNM) Reveals Promising Results in Phase 3 Trial of Varegacestat - GuruFocus
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacesta - The National Law Review
Immunome’s Varegacestat Phase 3 RINGSIDE Trial Results Presented at ASCO 2026 Show Progression-Free Survival Data in Desmoid Tumors - geneonline.com
Immunome announced positive clinical trial results for its drug Varegacestat. - Bitget
Immunome presents phase 3 trial results for desmoid tumor drug By Investing.com - Investing.com South Africa
Immunome presents phase 3 trial results for desmoid tumor drug - Investing.com
Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints - TradingView
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting - Business Wire
Does Barclays’ Bullish Stance Refocus Immunome’s (IMNM) Investment Narrative on Its ADC Platform? - simplywall.st
Immunome (IMNM) Receives a New Rating from Barclays - The Globe and Mail
IMNM Maintained by Truist Securities -- Price Target Raised to $37 - GuruFocus
Immunome Is Maintained at Buy by Truist Securities - Moomoo
Immunome Price Target Raised to $37.00/Share From $36.00 by Truist Securities - Moomoo
IMNM Initiates Coverage On Barclays -- Rating Set to Overweight - GuruFocus
Truist raises Immunome stock price target on desmoid tumor drug By Investing.com - Investing.com Australia
Truist Financial Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $37 - Moomoo
Barclays initiates Immunome stock coverage with overweight rating - Investing.com UK
Truist raises Immunome stock price target on desmoid tumor drug - Investing.com
Barclays Initiates Immunome at Overweight With $36 Price Target - marketscreener.com
Barclays initiates Immunome stock coverage with overweight rating By Investing.com - Investing.com Australia
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):